5-Fluorouracil (5-FU) is a key
drug for the treatment of
esophageal squamous cell carcinoma (ESCC); however, resistance to it remains a critical limitation to its clinical use. To clarify the mechanisms of
5-FU resistance of ESCC, we originally established 5-FU-resistant ESCC cells, TE-5R, by step-wise treatment with continuously increasing concentrations of
5-FU. The half maximal inhibitory concentration of
5-FU showed that TE-5R cells were 15.6-fold more resistant to
5-FU in comparison with parental
TE-5 cells. TE-5R cells showed regional copy number amplification of chromosome 1p including the DPYD gene, as well as high
mRNA and
protein expressions of
dihydropyrimidine dehydrogenase (DPD), an
enzyme involved in
5-FU degradation.
5-FU treatment resulted in a significant decrease of the intracellular
5-FU concentration and increase of the concentration of α-fluoro-ureidopropionic
acid (
FUPA), a metabolite of
5-FU, in TE-5R compared with
TE-5 cells in vitro. Conversely,
gimeracil, a DPD inhibitor, markedly increased the intracellular
5-FU concentration, decreased the intracellular
FUPA concentration, and attenuated
5-FU resistance of TE-5R cells. These results indicate that
5-FU resistance of TE-5R cells is due to the rapid degradation of
5-FU by DPD overexpression. The investigation of 5-FU-resistant ESCC with DPYD gene copy number amplification and consequent DPD overexpression may generate novel
biological evidence to explore strategies against ESCC with
5-FU resistance.